I
Cellular aging
Mitochondria, senescence pathways, and peptides investigated for energy, resilience, and cellular longevity.
Longevity Science · Peptide Research Institute
Human longevity will be written in molecules. Peptides are where that science begins.
ÆTERNUM LABS is a United States–based research institute dedicated to the scientific study of peptides in human longevity — cellular aging, metabolism, tissue repair, and resilience. We map mechanism, ground every entry in published literature, and uphold research-grade rigor.
0
Peptides studied across longevity pathways
0
Research axes — from metabolic to cellular aging
0
Claims without published evidence
↓ Scroll to enter the institute
01 — Longevity Science
Aging is a biological process. Peptides are how we study it at the molecular level.
Human longevity research is no longer only about lifespan statistics. It is about cellular energy, metabolic remodeling, tissue integrity, immune resilience, sleep architecture, and the molecular signals that decline with age.
Peptides sit at the center of that frontier. ÆTERNUM LABS studies that science with seriousness: mechanism first, published literature second, and an honest map of what evidence supports — and what remains open.
II
Metabolic longevity
Incretin-axis and exercise-mimetic research linking metabolism, body composition, and healthy aging trajectories.
III
Repair & resilience
Tissue repair, immune modulation, sleep and neuro pathways — systems that shape how organisms age.
02 — The Institute
A research institute for the science of human longevity.
ÆTERNUM LABS is a United States–based peptide research institute focused on longevity science. We study how selected peptides interact with aging biology — documenting mechanism, research axis, and published literature so the field advances on evidence, not hype.
PILLAR I
Longevity pathways, mapped
Every peptide is framed by its role in aging research: metabolic, mitochondrial, repair, GH axis, neuro, or immune.
PILLAR II
Peer literature as foundation
Mechanisms and findings are grounded in published science — from landmark journals to emerging preclinical models.
PILLAR III
Research use only
Built for scientists, laboratories, and longevity researchers. No clinical dosing guidance. No consumer wellness claims.
United States · Longevity Research
Rooted in the ecosystem where longevity biotech is being written.
ÆTERNUM LABS operates as a U.S.-based research laboratory with presence in the Cambridge, Massachusetts biotech corridor — where molecular science, translational research, and aging biology converge. That proximity is intentional: longevity science demands the same rigor as any serious biomedical field.
Our mission is not to sell hope. It is to document and study the peptides redefining how researchers approach human longevity — with intellectual honesty, analytical discipline, and a permanent focus on what the literature actually shows.
Longevity focus
Aging biology, not lifestyle branding
U.S. research base
Cambridge biotech ecosystem
Science first
Mechanism + published literature
03 — Scientific Research
Longevity science is built on evidence, not aesthetics.
At ÆTERNUM LABS, every peptide is studied as a window into aging biology. We connect laboratory practice with published literature so researchers can follow what is known about mechanism, what trials have measured, and where longevity science still has open questions.
01
Aging literature
Findings drawn from peer-reviewed longevity and biomedical research — NEJM, Lancet, Cell Metabolism and related journals — framed as science, never as protocols.
02
Evidence maturity
Each peptide is placed on a longevity evidence ladder: cellular models, animal aging studies, early human data, robust clinical literature.
03
Research-only framing
For scientists and longevity laboratories. No human dosing guidance. No anti-aging marketing claims.
04 — Longevity Peptide Library
Peptides under study in the science of aging.
Each entry is a longevity research molecule: internal code, biological axis, and a concise scientific profile. Explore pathways from metabolic remodeling and mitochondrial signaling to tissue repair, GH-axis research, neurobiology, and immune resilience.
RT-176
Metabolic
Retatrutide
Triple GIP/GLP-1/glucagon receptor agonist studied for metabolic remodeling and body composition.
Research Use Only
Open science dossier →
SP-322
Metabolic
SLU-PP-332
Synthetic ERRα/β/γ agonist studied as an “exercise mimetic” for mitochondrial biogenesis.
Research Use Only
Open science dossier →
MC-001
Cellular Longevity
MOTS-c
Mitochondrial-derived peptide involved in mitochondria-to-nucleus signaling and insulin sensitivity.
Research Use Only
Open science dossier →
GHK-Cu
Tissue Repair
GHK-Cu
Naturally occurring copper peptide studied for ECM remodeling and collagen synthesis.
Research Use Only
Open science dossier →
SS-31
Cellular Longevity
SS-31 (Elamipretide)
Mitochondria-targeted peptide studied for cardiolipin interaction and bioenergetics.
Research Use Only
Open science dossier →
FX-04
Cellular Longevity
FOXO4-DRI
Peptide studied in senolytic research for selective clearance of senescent cells via FOXO4–p53 disruption models.
Research Use Only
Open science dossier →
KPV-014
Immunomodulation
KPV
C-terminal α-MSH tripeptide fragment studied for anti-inflammatory activity via NF-κB.
Research Use Only
Open science dossier →
HGH-191
GH Axis
HGH Somatropin
Recombinant human growth hormone — reference compound for GH-axis signaling research.
Research Use Only
Open science dossier →
TES-021
GH Axis
Tesamorelin
GHRH analog studied for pulsatile GH secretion and visceral fat research programs.
Research Use Only
Open science dossier →
BPC-157
Tissue Repair
BPC-157
Gastric-derived pentadecapeptide widely studied in tissue repair and intestinal integrity models.
Research Use Only
Open science dossier →
TB-500
Tissue Repair
TB-500 (TB4 fragment)
Synthetic fragment associated with cell migration and repair models.
Research Use Only
Open science dossier →
EPI-04
Cellular Longevity
Epitalon
Synthetic tetrapeptide referenced in telomerase / epigenetic aging research.
Research Use Only
Open science dossier →
TA-1
Immunomodulation
Thymosin Alpha-1
Thymic peptide studied for immune modulation and T-cell function.
Research Use Only
Open science dossier →
SEL-442
Neuro/Sleep
Selank / Semax
Russian-origin peptides studied in anxiety and cognitive function models.
Research Use Only
Open science dossier →
DSIP-09
Neuro/Sleep
DSIP
Delta Sleep-Inducing Peptide studied in relation to deep-sleep architecture.
Research Use Only
Open science dossier →
No peptides in this longevity axis.
05 — Longevity Dossiers
The science behind every longevity peptide — open on the page.
Each dossier explains how the peptide is studied in aging and biomedical research: mechanism, longevity-relevant pathway, evidence tier, and what published literature has documented so far — paraphrased for scientists, never as usage instructions.
Cellular — in vitro
Animal — preclinical
Early human
Robust human
Longevity claims require evidence tiers — popularity is not science.
RT-176 Retatrutide Robust human
Mechanism
Triple agonist of the GIP, GLP-1, and glucagon receptors (Eli Lilly compound LY3437943). Among the most clinically advanced metabolic molecules of its generation.
Published literature
Phase 2 programs published in the New England Journal of Medicine and The Lancet documented substantial body-weight reductions and improved glycemic markers in type 2 diabetes contexts. A Nature Medicine substudy examined liver fat in metabolic disease. Presented here as research findings — not consumer advertising.
Limits & open questions
Late-stage clinical programs continue; framing remains Research Use Only on this archive.
SP-322 SLU-PP-332 Animal / cellular
Mechanism
Synthetic agonist of nuclear receptors ERRα/β/γ, described in the literature as an exercise mimetic — a molecule studied for pharmacologically echoing metabolic adaptations normally induced by aerobic exercise.
Published literature
Published research reports increased mitochondrial biogenesis, fatty-acid oxidation, and improved insulin sensitivity in diet-induced metabolic models. Structure–activity relationship work continues to map analogs for selectivity and metabolic stability.
Limits & open questions
Evidence is predominantly preclinical; human trial density is not yet comparable to incretin-class agents.
MC-001 MOTS-c Animal + translational
Mechanism
Mitochondria-encoded peptide from a short open reading frame within 12S rRNA — one of few known peptides with this origin. Acts on AMPK-axis biology via folate-cycle signaling, with skeletal muscle as a primary target tissue.
Published literature
Landmark work in Cell Metabolism links MOTS-c to retrograde mitochondria-to-nucleus signaling. Animal studies demonstrate protection against age- and diet-related insulin resistance.
Limits & open questions
Translational human programs remain emerging relative to the strength of mechanistic and animal data.
GHK-Cu GHK-Cu Early–robust human
Mechanism
Tripeptide naturally present in human plasma; concentrations decline significantly with age. Documented for decades in tissue-regeneration literature.
Published literature
Controlled comparisons with vitamin C and retinoic acid report favorable collagen-related outcomes for GHK-Cu in topical research settings. Reviews discuss metalloproteinase modulation, angiogenesis, and extracellular matrix remodeling.
Limits & open questions
Much of the densest human literature is topical/regenerative; systemic research contexts differ.
SS-31 SS-31 (Elamipretide) Early–robust human
Mechanism
Tetrapeptide engineered to enrich in the inner mitochondrial membrane and interact with cardiolipin — a phospholipid essential to electron transport chain architecture.
Published literature
Among the rare mitochondrial peptides with substantial human clinical investigation: aging bioenergetics, Barth syndrome, heart failure, and age-related macular degeneration research programs. Mechanistic literature describes interactions relevant to mitochondrial membrane transport.
Limits & open questions
Indication-specific programs vary in maturity; not all research axes have equivalent trial density.
FX-04 FOXO4-DRI Animal / cellular
Mechanism
FOXO4-DRI is a research peptide designed to interfere with the FOXO4–p53 interaction in senescent-cell models. In published preclinical work, disrupting this interaction has been studied as a strategy to induce apoptosis preferentially in senescent cells while sparing non-senescent populations in certain experimental systems.
Published literature
Preclinical literature in aging and cellular senescence models examines FOXO4-related interventions as part of the broader senolytic research axis. Evidence remains primarily at cellular and animal-model density; translational human programs are not established at the level of robust multi-trial clinical literature.
Limits & open questions
Human evidence is limited. Present here strictly as a research-literature entry — not as a therapeutic claim or usage guidance. Research Use Only.
KPV-014 KPV Animal / cellular
Mechanism
C-terminal fragment of α-MSH (positions 11–13). Literature describes retained anti-inflammatory activity without classic pigmentary effects, via receptor-independent NF-κB pathway inhibition.
Published literature
Preclinical studies report activity in animal models of colitis, dermatitis, and airway inflammation.
Limits & open questions
Human clinical density remains limited compared with larger immunomodulatory peptides.
HGH-191 HGH Somatropin Robust human (reference)
Mechanism
Recombinant human growth hormone, sequence-identical to endogenous GH. The longest-standing reference point in GH-axis research.
Published literature
Decades of clinical literature address protein synthesis, body composition, bone density, and lipid metabolism via the GH/IGF-1 axis. Included here strictly as a scientific reference compound for the axis — not as a consumer product.
Limits & open questions
Regulated medicine in many jurisdictions; this archive does not provide clinical-use guidance.
TES-021 Tesamorelin Robust human
Mechanism
Synthetic analog of human GHRH, modified for resistance to DPP-IV degradation, studied for stimulatory action on pulsatile GH secretion.
Published literature
Phase 3 programs underpin its regulatory history. Literature documents visceral adipose and metabolic endpoints; additional lines of work explore cognitive endpoints and liver fat in specific populations (including work associated with Archives of Neurology and The Lancet HIV).
Limits & open questions
Present strictly in research-literature framing; not dosing or clinical advice.
BPC-157 BPC-157 Animal (extensive)
Mechanism
Fifteen–amino-acid peptide derived from a protective protein in gastric juice. Extensively studied in preclinical tissue-repair research.
Published literature
More than fifty published studies span ulcer healing, intestinal barrier integrity, and tendon/muscle repair models. Reviews note consistent protective signals across multiple gastrointestinal injury paradigms.
Limits & open questions
Human evidence remains limited relative to the density of animal literature — stated here as scientific honesty.
TB-500 TB-500 (TB4 fragment) Mixed / preclinical-heavy
Mechanism
Synthetic fragment related to the actin-binding region of Thymosin Beta-4. Core documented mechanism: G-actin sequestration with downstream effects on cell migration and angiogenesis.
Published literature
Parent TB4 literature is denser in corneal and skin contexts; cardiac and musculoskeletal models are largely preclinical. Scoping reviews map heterogeneous evidence quality across tissues.
Limits & open questions
Do not conflate fragment research with full-length TB4 clinical programs.
EPI-04 Epitalon Cellular / limited replication
Mechanism
Synthetic tetrapeptide Ala-Glu-Asp-Gly associated with the Khavinson bioregulation lineage; frequently referenced in telomerase-activation discussions.
Published literature
Human cell-line work reports effects on telomerase activity and telomere length in aged cells. Long-term rodent work from originating groups documents lifespan-related endpoints.
Limits & open questions
Evidence base historically concentrated in Russian literature, with limited independent Western replication to date.
TA-1 Thymosin Alpha-1 Robust human
Mechanism
Twenty-eight–amino-acid peptide originally isolated from the thymus; studied extensively for immune response modulation and T-cell function.
Published literature
Approved as thymalfasin/Zadaxin in multiple countries for chronic hepatitis and as an immune adjuvant. Clinical literature includes severe infection contexts and oncology-adjuvant investigation.
Limits & open questions
Jurisdiction-specific medicinal status does not change the Research Use Only framing of this general archive.
SEL-442 Selank / Semax Animal + regional tradition
Mechanism
Complementary pair: Selank acts with a GABA-related anxiolytic profile in models; Semax, derived from an ACTH fragment, is studied for rapid BDNF elevation.
Published literature
Journal of Neurochemistry work documented increased BDNF in rodent basal forebrain after Semax administration. Broader literature includes cerebral ischemia models. Regional clinical traditions should not be equated with global Phase 3 density.
Limits & open questions
Distinguish regional use history from multi-region, multi-trial evidence standards.
DSIP-09 DSIP Historical + animal
Mechanism
Nonapeptide first linked to increased delta-wave EEG activity in classic isolation studies — associated with deep, restorative sleep architecture in research descriptions.
Published literature
Literature since the 1970s explores neurotransmitter modulation (GABA, serotonin, dopamine), anticonvulsant models, and recovery paradigms after experimental stroke.
Limits & open questions
Avoid sleep-product marketing tone; historical observation is not modern Phase 3 proof.
06 — Scientific Rigor
Longevity research demands molecular certainty.
If peptides are to inform the science of aging, identity and purity cannot be optional. ÆTERNUM LABS follows a four-step analytical path so every research material is treated with laboratory discipline.
01
Solid-phase synthesis
Sequence-defined production under controlled parameters — the starting point for research-grade peptides.
02
Preparative HPLC purification
Isolation of the target peptide for longevity research, with removal of byproducts and residues.
03
Mass spectrometry confirmation
Identity confirmed against theoretical mass — essential when studying aging-related mechanisms.
04
Purity certificate & custody
Certificate of Analysis and chain of custody for qualified longevity research partners.
Reading Longevity Evidence
How to read a longevity peptide study.
CellAging models in vitro
AnimalPreclinical longevity models
Early humanEarly clinical / limited human data
Robust humanExtensive clinical literature
A longevity claim is only as strong as its evidence tier.
Research Collaboration
Collaborate on the science of longevity.
ÆTERNUM LABS opens research access, scientific dossiers, and analytical documentation to longevity researchers, laboratories, and institutional partners studying peptide biology and human aging. Direct scientific collaboration — not a consumer signup.
research@aeternumlabs.science
Headquarters
Research headquarters — Boston.
ÆTERNUM LABS
300 Pier 4 Blvd.
Boston, MA 02210
United States